Article
Early radiographic response to epidermal growth factor receptor-tyrosine kinase inhibitor in non-small cell lung cancer patients with epidermal growth factor receptor mutations: A prospective study.
Biomedical journal - 1 Jan 2000
Chang John W C, Hou Ming-Mo, Hsieh Jia-Juan, Cheung Yun-Chung, Wang Hung-Ming, Chen Jen-Shi, Wang Cheng-Hsu, Chen Chih-Hung, Yeh Kun-Yun, Ou Li-Ying, Hsieh Chia-Hsun, Wu Hong-Dar Isaac, Chen Ying-Tsong, Chang Il-Chi, Huang Shiu-Feng
Abstract excerpt
BACKGROUND: The time schedules for response evaluation of epidermal growth factor receptor-tyrosine kinase Inhibitor (EGFR-TKI) in non-small cell lung cancer (NSCLC) patients are still ill-defined. METHODS: Stage IIIB/IV patients with histologically proven NSCLC were enrolled in this study if the tumor cells bore EGFR mutations other than T790M. Eligible patients were treated with either 250 mg of gefitinib or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.